Neuroimaging Predictors of Survival, Pathology, and Molecular Profiles

Dr. Gutman received his bachelor's in chemistry from Penn State. Following college, he entered the MD/PhD program at Emory and received his PhD in Neuroscience, and MD, in2005.  He subsequently completed a Psychiatry residency at Emory University in June 2009.  Since then, he has joined CCI as a research scientist.  His area of research interest during residency focused on understanding the neurocircuitry of depression, with a focus on advanced neuroimaging techniques including diffusion tensor imaging.  While at CCI, he has focused on the analysis and management of digital pathology and radiology images from Glioblastoma Multiforme (GBM). He holds an appointment as Assistant Professor with the Department of Biomedical Informatics at Emory University School of Medicine

Focusing Genomics on Human Genetics

Richard Gibbs talk about genomics, and sequencing genome, he received a B.Sc.(Hons) in 1979 and a Ph.D. in Genetics and Radiation Biology in 1985 at the University of Melbourne, Melbourne, Australia. He subsequently moved to Houston as a Postdoctoral Fellow at Baylor College of Medicine to study the molecular basis of human X-linked diseases and to develop technologies for rapid genetic analysis. During this period, he also developed several fundamental technologies for nucleic acid analysis. In 1991, he joined the faculty at BCM and played a key role in the early planning and development phases of the International Human Genome Project. In 1996, he established the Human Genome Sequencing Center (HGSC) when Baylor was chosen as one of six worldwide sites to complete the final phase of the project. He currently holds the rank of Director and Professor.

Breast Cancer Medicine: Today and Tomorrow

Medical oncologist Larry Norton of Memorial Sloan-Kettering Cancer Center explains how new information about the biology of breast cancer is paving the way for a more targeted approach to chemotherapy for breast cancer. Advances in the field of molecular genetics have shown that breast cancer can be caused by several genetic mutations. Researchers are using this information to develop more effective therapies that target these genes.

Molecular Testing in Breast Cancer: Will it Become Standard Practice?

How has gene expression profiling impacted the way we diagnose and treat breast cancers? Kimberly Allison, MD, Assistant Professor, Department of Pathology at the University of Washington discusses how research using gene expression signatures have been used to identify specific subtypes of breast cancer and how these are integrated into traditional classification schemes. In addition, we will explore the development of clinically available gene expression array-based tests that are designed to give prognostic and predictive information tailored to individual breast cancer patients and discuss current limitations of these tests

Molecular Assays for Colorectal Cancer Care

Molecular assays for risk stratification for cancer and for the early detection of cancer are currently being developed and are beginning to be used in clinical care. Likewise, molecular assays are being developed as predictive and prognostic markers for cancer. The state-of-the art of currently available risk stratification assays and molecular screening assays for colorectal cancer will be discussed. Current developments in the generation of predictive and prognostic markers for colorectal cancer will also be discussed. Finally, future directions for molecular assays for colorectal cancer will be reviewed.

Cell Biology: How Do Cells Make Decisions?

The moderator is Marc Kirschner, PhD, John Franklin Enders University Professor of Systems Biology, Department of Systems Biology, Harvard University; the speaker is Richard Losick, PhD, Maria Moors Cabot Professor of Biology, Department of Molecular and Cellular Biology, Harvard University; and panelists are Hana El Samad, assistant professor, Biochemistry & Biophysics, UC Berkeley/UCSF Graduate Group in Bioengineering; and Jonathan Weissman, PhD, professor of Cellular and Molecular Pharmacology and of Biochemistry and Biophysics at UCSF.

Cancer: How Do We Prevent Metastasis?

In this lecture, titled "Cancer: How Do We Prevent Metastasis?," the moderator is Nobel laureate Harold Varmus, MD, president of Memorial Sloan-Kettering Cancer Center; the speaker is Joan Massagué, PhD, chair of the Cancer Biology and Genetics Program in the Sloan-Kettering Institute; and panelists are Zena Werb, PhD, professor and vice chair, Department of Anatomy at UCSF, and Marc Shuman, MD, professor of medicine and of urology, and Cancer Research Institute at UCSF.